

GHWP TC 2025

Contents





- Guidance Development Direction
- Guidance Development Status
- Guidance Adoption Assessment
- TC Training Programs

TC Top Priorities

✓ Accelerate Guidance Development

- Quarterly meetings between TCLT & WG LT.
- Working Groups (WGs) confirm new work item proposals, guidance development plan and timelines.
- Establish guidance review rules with TC advisors.

Person-in-charge: Li Jun, Miang, Vera

✓ Enhance TC Capacity Building

- Develop TC training plan and conduct trainings with CB.
- All training invitations/slides/videos should be posted on GHWP website.
- Support trainings of GHWP Academy, especially propose the trainings of GHWP Guidance.

Person-in-charge: Adelheid, Vera

✓ Guidance Adoption Assessment


- Continue the assessment within GHWP member countries/regions.
- Solicit the potential guidance from WGs for assessment.

Person-in-charge: Li Jun, Vera, Yasha, Victoria

✓ Guidance Clean-up

WGs conduct to clean up the guidance
 Person-in-charge: Miang, Adelheid





✓ Improve TC WG Advisors Engagement

- Establish Guidance Review Procedure and Rules for TC Advisors.
- Improve TC advisor engagement in all GHWP TC events.

Person-in-charge: Mohammed, Miang, Adelheid





✓ TC Leaders Meeting

- Develop the meeting agenda and topics for TCLT meeting in Egypt in June.
- Invite all WG Chairs and Cochairs to join the meeting and update the work progress and guidance development status.

Person-in-charge: Miang, Victoria



✓ GHWP & TC Annual Meeting

- Finalize and review the guidance for endorsement in Annual Meeting.
- Invite WG leaders and members to join annual meeting.

Person-in-charge: all






Guidance Development

Guidance Development Direction




Guidance Development Status





Current Guidance Distribution



Guidance to be Endorsed in 2025 Annual Meeting

No.	WG	Guidance to be Endorsed	
1	1,2,3	Guidance on Determining of Lead Authority and Communication Process for Combination Products (WG1 lead)	
2	Guidance on pre-market requirement for artificial intelligence/machine learning based computer-aided detection (CADe) and computer-aided diagnosis (CADx) software as a medical device		
3		Playbook for Design and Implementation of Active Post-Market Surveillance System	
4	4	Definition and Classification of Field Corrective Actions, including Field Safety Corrective Actions, Recalls and Non-Safety related Field Corrective Actions	
5		Guidance for Remote Inspections of Medical Device Manufacturers	
6	7	Guidance for Control of Sterilized and Implantable Medical Device	
7		White Paper on Overview of Quality Management System Requirements and Implementation in GHWP member country or region	
8	9	UDI Application Guidance Considerations for Manufacture to Facilitate an Effective UDI Implementation	

Drafting Guidance

No.	WG	Guidance Document	
1	1,2,3	Guidance for Additional Considerations to Support Pre-market Conformity Assessment of AI-based SaMD for Image Analysis in Digital Pathology	
2	5,3	Guidance for SaMD clinical evidence and clinical evaluation (WG5 lead)	
3	8,7	Guidance on the Validation of Processes for Production (WG8 lead)	
4	1	White Paper on the Comparative Study for Lifetime of Active Medical Devices Program Application (NWIP)	
5	2	Labelling for In Vitro Diagnostic Medical Devices	
6		Guidance Document on Qualification of Medical Device Software	
7	3	Guidance document on Risk Categorization of Software as a Medical Device	
8	3	The terms and definitions of digital therapeutics medical devices	
9		AI/ML based SaMD change submission requirement – Comparison of requirements from key jurisdictions	
10	4	Medical Device Post-Marketing Surveillance (MD-PMS): Transition from Passive to Active	
11	8	White paper on Role of Standards in the Regulation of Medical Devices	
12	9	Medical Device Nomenclature Insights of International Common Medical Device Nomenclature Systems	
13	CERP	Guidelines on Quality Management System for Technical Evaluation (NWIP)	
14		General Procedure of Common Evaluation Reliance Practice (NWIP)	



Guidance Adoption Assessment

Guidance Adoption Assessment (1st Round in 2024)

Feedback from 4 member countries/regions: Cuba, Hong Kong, Thailand, China

WG	Document No.	Description	China	Hongkong	Cuba	Thailand
1,2,3	GHWP/WG1-WG2- WG3/F002:2023	Principles of Regulatory Requirements for Electronic Instructions for Use (eIFU)	Not Implement	Not Applicable	Partially Adopted	Not Applicable
1,2,3	GHWP/WG2-WG1- WG3/F001:2023	Categorisation of Changes to a Registered Medical Device	Partially Adopted	Not Applicable	Fully Adopted	Not Applicable
1,2,3	GHWP/WG2-WG1- WG3/F001:2021	Regulatory Mechanism for Medical Devices Including In Vitro Diagnostic Medical Devices and Software as Medical Devices During A Public Health Emergency	Fully Adopted	Not Applicable	Fully Adopted	Not Applicable
2	GHWP/WG2/F001:2023	Guidance for Additional Considerations to support Conformity Assessment of In vitro Companion Diagnostic Medical Device	Fully Adopted	Not Applicable	Not Implement	Not Applicable
7	GHWP/WG7/F003:2023	Guidance for Audit Supplier to Medical Device Manufacturers	Fully Adopted	Not Applicable	Fully Adopted	Not Applicable
7	GHWP/WG7/F004:2023	Guidance Document on the Risk-Based Approach to Quality Management System Aspects: ISO13485:2016	Fully Adopted	Not Applicable	Fully Adopted	Fully Adopted
9	GHWP/WG9/F001:2023	UDI Rules	Fully Adopted	Not Applicable	Not Implement	Not Applicable

Guidance Adoption Assessment (2nd Round in 2025)

11 Guidance Documents Selected for Assessment

Selection criteria for guidance: GHWP original guidance; Implemented within 5 years

Consultation Scope and Period: GHWP Member countries/regions & WG Chairs; Deadline: August 30

WG	Doc. No.	Guidance Guidance
1,2,3	GHWP/WG1-WG2-WG3/F002:2023	Principles of Regulatory Requirements for Electronic Instructions for Use (eIFU)
1,2,3	GHWP/WG2-WG1-WG3/F001:2024	Change Management to Registered Medical Devices
1,2,3	GHWP/WG2-WG1-WG3/F001:2023	Categorisation of Changes to a Registered Medical Device
1,2,3	GHWP/WG2-WG1-WG3/F001:2021	Regulatory Mechanism for Medical Devices Including In Vitro Diagnostic Medical Devices and Software as Medical Devices During A Public Health Emergency
2	GHWP/WG2/F001:2023	Guidance for Additional Considerations to support Conformity Assessment of In vitro Companion Diagnostic Medical Device
7	GHWP/WG7/F002:2024	Guidance Document for Medical Device Organizations-Product Localisation for Manufacturing and Importation
7	GHWP/WG7/F003:2023	Guidance for Audit Supplier to Medical Device Manufacturers
7	GHWP/WG7/F004:2023	Guidance Document on the Risk-Based Approach to Quality Management System Aspects: ISO13485:2016
9	GHWP/WG9/F001:2023	UDI Rules
8	GHWP/WG8/F001:2023	Medical Gas System- Essential Principals of Safety and Performance
9	GHWP/WG9/F001:2024	Creation and Placement of Unique Device Identifier



Training Programs

TC Training Programs in 2025





GHWP Academy

- 3rd Guangzhou Training
- 4th Chongqing Training



In-Country Training

• Nov. 13, Oman






CB Training at GHWP Annual meetings & TC meetings

- June, Egypt
- Dec. Thailand



TC Online Training

- every month
- Online training



TC Training Programs

2024 Completed Trainings:



10

May	WG7	Overview of QMS in Japan	
June	WG9	GHWP UDI Rule	
June	WG7	Guidance on Risk Based Approach to QMS aspects ISO13485:2016	
June	WG1	e-IFU and e-labelling	
July	WG5	Systematic review and meta - analysis on the performance reports	
Oct.	WG7	A Guide to Understanding Best Practices in Audit Life Cycle Management	
Oct.	WG3	Guidance Document on Qualification of Medical device Software	
Nov.	WG4	Introduce the Adverse Event Terminology (AET) system across different jurisdictions	
Nov.	 Medical Gas System (MGS) – Essential Principles of WG8 Safety and Performance (EPSP) – Standards for Demonstrating Compliance 		
Dec.	WG7	Comparison study of ISO 13485 vs. QMS requirements in GHWP member countries or regions	

2025 Completed & Ongoing Trainings:



13

Aug.	WG1	Change Management to Registered Medical Devices
Jan.	WG2	GHWP Guideline Reagent Replacement and Instrument Family Policy
July	WG3	White Paper: Software as a Medical Device (SaMD) Pre- Market Submission Requirement – Comparison of requirement from Key jurisdictions
Nov.	WG4	Post-Market Control Strategies for End-of-Life Products
May	WG7	Digital Application in Quality Management System
June	WG7	Medical Device Cybersecurity
Oct.	WG7	Sharing of QMS Requirement and Practice in Chinese Taipei
May	WG9	Creation and Placement of UDI
Nov.	WG9	UDI Data Elements
твс	WG5	Post Market Clinical Studies-Post-market surveillance
твс	WG7	TBC
твс	WG8	Role of Standards
твс	CERP	ТВС

TC together



- Oriented to members' needs
- Oriented to regulatory and industrial needs
- Oriented to cutting-edge innovation



- Develop high-quality guidance
- Continuously Enhance Capacity Building by Diverse Trainings
- Invite regulators & experts from GHWP member countries/regions to join TC and WGs



- Fully exert GHWP's unique strengths (joint efforts by regulators and industry) and initiative of members
- Enhance GHWP competitiveness and influence







